-
151.发明授权公开(公告)号：US11919923B2
公开(公告)日：2024-03-05
申请号：US17996430
申请日：2021-04-16
Applicant: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES , WUHAN INSTITUTE OF VIROLOGY, CHINESE ACADEMY OF SCIENCE , XINJIANG TECHNICAL INSTITUTE OF PHYSICS AND CHEMISTRY, CHINESE ACADEMY OF SCIENCES , VIGONVITA LIFE SCIENCES CO., LTD.
Inventor： Yuanchao Xie , Gengfu Xiao , Yang He , Leike Zhang , Haji Akber Aisa , Hualiang Jiang , Jingshan Shen
CPC classification number: C07H7/06 , A61P31/14 , A61P31/16 , C07B2200/05
Abstract: The present invention relates to an antiviral application of nucleoside analogs. Specifically, the present invention relates to uses of nucleoside analogs and a pharmaceutical composition thereof as: (a) inhibitors for inhibiting the replication of coronaviruses, influenza viruses, respiratory syncytial viruses, flaviviridae viruses, filoviridae viruses and/or porcine epidemic diarrhea virus (PEDV); and/or (b) medicines for treating and/or preventing and mitigating diseases caused by coronavirus, influenza virus, respiratory syncytial virus, flaviviridae virus, filoviridae virus and/or porcine epidemic diarrhea virus (PEDV) infections. The nucleoside analogs according to the invention may treat and/or prevent and mitigate respiratory infection, pneumonia (COVID-19) and other related diseases caused by 2019 novel coronavirus infection.
-
152.发明授权公开(公告)号：US11731965B2
公开(公告)日：2023-08-22
申请号：US16639394
申请日：2018-08-14
Applicant: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES , TOPHARMAN SHANGHAI CO., LTD.
Inventor： Yang He , Xiangrui Jiang , Jianfeng Li , Yu Wang , Zhen Wang , Weiming Chen , Fuqiang Zhu , Chunhui Wu , Rongxia Zhang , Jingshan Shen , Hualiang Jiang
IPC: C07D455/03 , C07D498/14 , A61P25/20
CPC classification number: C07D455/03 , A61P25/20 , C07D498/14
Abstract: The present invention provides a tetrahydroprotoberberine compound represented by the formula (I), enantiomers, diastereomers, racemates and mixtures thereof, and pharmaceutically acceptable salts, crystalline hydrates and solvates thereof. The invention also provides a method for preparing the compound and the use thereof in the preparation of a medicament for preventing and/or treating central nervous system diseases.
-
公开(公告)号：US20230138310A1
公开(公告)日：2023-05-04
申请号：US17759807
申请日：2020-03-26
Applicant: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES , FRONTIER BIOTECHNOLOGIES INC.
Inventor： Hong LIU , Jian LI , Wenhao DAI , Jingjing PENG , Xiong XIE , Shulei HU , Chunpu LI , Yechun XU , Haitao YANG , Leike ZHANG , Haixia SU , Hualiang JIANG , Zhenming JIN , Gengfu XIAO , Kaixian CHEN
IPC: C07D403/12 , C07D405/12 , C07D413/12 , C07D401/12 , C07D411/12 , C07D471/04 , C07D207/12 , A61P31/14
Abstract: Use of an aldehyde-based compound as represented by general formula I, a pharmaceutical composition, a pharmaceutical salt, an enantiomer, a diastereomer and a racemic compound thereof as a novel coronavirus 2019 (2019-nCov) 3CL protease inhibitor in preparation of a medicament for treating and/or preventing and relieving respiratory tract infections, pneumonia and other related diseases caused by the novel coronavirus infection 2019.
-
154.发明申请公开(公告)号：US20230080811A1
公开(公告)日：2023-03-16
申请号：US17792474
申请日：2021-01-14
Inventor： Yong GAN , Shiyan GUO , Yinyin SUN , Quanlei ZHU
Abstract: Provided are a long-acting ropivacaine pharmaceutical composition, a preparation method therefor and use thereof. The pharmaceutical composition comprises: ropivacaine; a pharmaceutical solvent; a pharmaceutical phospholipid; a pharmaceutical oil; and an efficacy enhancer, an optional antioxidant and an optional acid-base regulator. The pharmaceutical composition has a controllable release behavior and a sustained release effect, can significantly reduce the peak plasma concentration of the drug, maintain a stable plasma concentration in the body, prolong the effective treatment time, reduce the effective therapeutic dose, improve the utilization of the drug, and reduce the risk of neurotoxicity. The pharmaceutical composition has a long-acting analgesic effect and can be used for pain treatment.
-
公开(公告)号：US20220395476A1
公开(公告)日：2022-12-15
申请号：US17765354
申请日：2020-09-29
Inventor： Baohong JIANG , Xianjing ZHANG , Yuchao DING , Ziyi ZHAI
IPC: A61K31/12 , A61K31/05 , A61K31/192 , A61K31/216 , A61K36/185 , A61K31/37
Abstract: Provided are a drug for treating artery-related diseases and the use thereof. Specifically, provided are the use of a class of compounds of formula I in the treatment of artery-related diseases. Experiments show that the compounds of formula I have a significant effect on aneurysm, intramural hematoma and/or atrerial dissection.
-
Patent Agency Ranking
公开(公告)号：US11498927B2
公开(公告)日：2022-11-15
申请号：US17289642
申请日：2019-10-08
Inventor： Bing Zhou , Wei Tang , Xiangbo Yang , Huimin Lu , Mengying Gao , Yaxi Yang , Huijin Feng
IPC: C07D513/04 , A61P37/06 , C07D401/12 , C07D401/14 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14 , C07D487/04
Abstract: The present invention relates to a heterocyclic amide inhibiting RIP1 kinase and the use thereof, and specifically, to a compound of formula I, its pharmaceutically acceptable salts, stereoisomers, enantiomers, diastereomers, atropisomers, optical isomers, racemates, polymorphs, solvates or isotopically labeled compounds, a pharmaceutical composition comprising the compound, and the pharmaceutical use thereof. The compound is particularly effective for treatment of diseases or disorders mediated by RIP1 kinase.
-
157.发明申请公开(公告)号：US20220324869A1
公开(公告)日：2022-10-13
申请号：US17640424
申请日：2020-09-03
Inventor： Wenhu DUAN , Meiyu GENG , Hefeng ZHANG , Jian DING , Jing AI , Xia PENG , Yinchun JI
IPC: C07D487/04 , A61P35/00 , C07D401/14 , C07D405/14 , C07F7/08
Abstract: A compound having Axl and c-Met kinase inhibitory activity, a preparation method therefor and an application thereof are provided. Specifically, provided herein are a compound having the structure represented by formula (I), a preparation method therefor and an application thereof in the preparation of a medication for the treatment and/or prevention of tumor-associated diseases and/or kinase-related diseases.
-
公开(公告)号：US20220280589A1
公开(公告)日：2022-09-08
申请号：US17631807
申请日：2020-08-05
Applicant: SHANGHAI GREEN VALLEY PHARMACEUTICAL CO., LTD. , SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
Inventor： Meiyu Geng , Guangqiang Sun , Xinyi Wang , Jing Zhang , Teng Feng
Abstract: Provided is a use of an agent for regulating an amino acid level in preparing a drug for treating Alzheimer's disease in a subject.
-
公开(公告)号：US20220280578A1
公开(公告)日：2022-09-08
申请号：US17631738
申请日：2020-08-05
Applicant: SHANGHAI GREEN VALLEY PHARMACEUTICAL CO., LTD. , SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
Inventor： Meiyu Geng , Guangqiang Sun , Xinyi Wang , Jing Zhang , Teng Feng
IPC: A61K35/741 , A61K49/00 , A61K38/17 , A61P25/28
Abstract: The present invention relates to the treatment of Alzheimer's disease. Provided is the use of an reagent for regulating the relative abundance of intestinal microorganisms in the preparation of a medicament for treating Alzheimer's disease in a subjet.
-
公开(公告)号：US11406652B2
公开(公告)日：2022-08-09
申请号：US17256889
申请日：2019-06-28
Applicant: GREEN VALLEY (SHANGHAI) PHARMACEUTICAL CO., LTD. , SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
Inventor： Meiyu Geng , Xianliang Xin , Zhenqing Zhang , Jian Ding
IPC: A61P3/10 , A61K31/715 , A61K31/7032 , A61K31/702 , A61K31/7012 , A61K31/7016
Abstract: The present invention relates to the use of mannuronic diacid oligosaccharide composition in the treatment of diabetes.
-
-
-
-
-
-
-
-
-
Search Results
257
records
(took 0.057 seconds)
